{"product_id":"rgnx-vrio-analysis","title":"REGENXBIO Inc. (RGNX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking the secrets to REGENXBIO Inc. (RGNX)'s competitive edge starts here! This VRIO analysis distills exactly how their current resources measure up on the crucial dimensions of Value, Rarity, Inimitability, and Organization. Discover the core strengths - or potential weaknesses - that define their market position and prepare to see the full, game-changing breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 1. Proprietary NAV Technology Platform (AAV Vectors)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at the core engine of REGENXBIO, their NAV Technology Platform, which is essentially the patented delivery truck for their gene therapies. This platform is what underpins their entire business model, both for their own pipeline and for their licensing deals. Honestly, if you want to understand the long-term value here, you have to look at how well they are monetizing this IP right now.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Foundational Delivery System and Revenue Generation\u003c\/h3\u003e\n\u003cp\u003eThe value proposition is clear: this patented delivery system lets REGENXBIO get their therapeutic cargo into the right cells. It’s the foundational piece for developing multiple product candidates, like RGX-202 for Duchenne muscular dystrophy and surabgene lomparvovec for retinal diseases. The market is already validating this value through partnerships. For instance, they received a $110.0 million upfront payment from Nippon Shinyaku in March 2025, and they monetized royalties for $144.5 million in May 2025. This shows the platform is actively creating tangible financial value, not just theoretical potential.\u003c\/p\u003e\n\u003cp\u003eHere’s a quick look at their recent top-line performance, which is heavily influenced by these licensing and royalty streams:\u003c\/p\u003e\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eMetric\u003c\/th\u003e\n    \u003cth\u003eValue (Q3 2025)\u003c\/th\u003e\n    \u003cth\u003eContext\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eTotal Revenues\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$29.7 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eFor the three months ended September 30, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash \u0026amp; Marketable Securities\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e$302.0 million\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eAs of September 30, 2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCash Runway Guidance\u003c\/td\u003e\n    \u003ctd\u003eInto early 2027\u003c\/td\u003e\n    \u003ctd\u003eBased on current operational plans\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cp\u003eThis platform is what keeps the lights on while the internal pipeline matures. Their cash position of $302.0 million as of September 30, 2025, is partly built on these licensing deals.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: A Unique Vector Library\u003c\/h3\u003e\n\u003cp\u003eThe rarity stems from the specific, optimized set of novel AAV (Adeno-Associated Virus) vectors they have engineered and patented. While the underlying science of AAV vectors is known in the field, REGENXBIO claims a unique, proprietary set, described as over 100 novel AAV vectors. This specific library is not something a competitor can just whip up next quarter. It represents years of focused development and screening, which is rare in the biotech space where IP is everything.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Patent Protection vs. Scientific Knowledge\u003c\/h3\u003e\n\u003cp\u003eImitability is high, but not absolute. The core science behind AAV vectors is public domain, so someone could try to engineer similar vectors. However, the specific, optimized vectors are protected by patents. Think of it this way: everyone knows how to bake a cake, but only one person has the secret recipe for a specific, award-winning frosting. REGENXBIO’s patent estate is the barrier here, even if the general concept is understood. The fact that they are advancing multiple late-stage assets, like clemidsogene lanparvovec (RGX-121) with a PDUFA date set for February 8, 2026, proves the platform’s utility is hard to mimic effectively enough to reach that stage.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: Licensing and Pipeline Execution\u003c\/h3\u003e\n\u003cp\u003eREGENXBIO is definitely organized around this asset. They don't just sit on the IP; they actively license it out, which is a smart way to generate non-dilutive capital and gain external validation. Their structure supports both internal development and external partnerships. They are advancing a late-stage pipeline targeting serious diseases, which is the ultimate proof of organizational focus. They are positioning to become a commercial company early next year, which requires a tight operational structure to handle manufacturing and launch.\u003c\/p\u003e\n\u003cp\u003eKey operational achievements showing organizational strength include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePivotal enrollment completed for RGX-202 in October 2025.\u003c\/li\u003e\n\u003cli\u003eSecured a $250 million royalty agreement with Healthcare Royalty in Q2 2025.\u003c\/li\u003e\n\u003cli\u003eAmended AbbVie collaboration with potential $200 million in new milestones.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage: Sustained Potential\u003c\/h3\u003e\n\u003cp\u003eThe combination of strong, patented IP (Imitability) and active, revenue-generating licensing (Organization\/Value) points toward a sustained competitive advantage, provided the pipeline delivers. The platform itself is the moat. If their next-gen vectors prove superior in clinical trials - for example, if RGX-202 shows best-in-class results - that advantage will solidify. If onboarding takes 14+ days, churn risk rises, but for a one-time gene therapy, the upfront delivery success is what matters most, and that rests on the NAV vectors.\u003c\/p\u003e\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 2. Late-Stage Clinical Pipeline Momentum\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Holds the near-term potential for blockbuster revenue and market entry across rare and common diseases.\u003c\/p\u003e\n\n\u003cp\u003eThe near-term value is anchored by three distinct, late-stage assets poised for potential market entry:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRGX-121 for MPS II, on track to be the potential first gene therapy and one-time treatment approved for MPS II.\u003c\/li\u003e\n\u003cli\u003eRGX-202 for Duchenne Muscular Dystrophy (DMD).\u003c\/li\u003e\n\u003cli\u003eABBV-RGX-314 for chronic retinal diseases, including wet Age-related Macular Degeneration (wet AMD) and Diabetic Retinopathy (DR).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Many biotechs have pipelines, but three late-stage assets targeting high-need areas is less common.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Competitors cannot easily replicate the clinical data or regulatory progress already achieved.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. The company is clearly focused, prioritizing RGX-121, RGX-202, and ABBV-RGX-314.\u003c\/p\u003e\n\u003cp\u003eFinancial resources as of September 30, 2024, included cash, cash equivalents, and marketable securities of $278.6 million, expected to fund operations into 2026.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eKey Clinical Milestone\/Data Point\u003c\/th\u003e\n\u003cth\u003eTarget\/Expected Date\u003c\/th\u003e\n\u003cth\u003eKey Metric\/Market Potential\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-121\u003c\/td\u003e\n\u003ctd\u003eMPS II (Hunter Syndrome)\u003c\/td\u003e\n\u003ctd\u003eBLA Submission Completion\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003ctd\u003eGlobal Hunter Syndrome treatment market expected to reach $1.78 billion by 2030.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-121\u003c\/td\u003e\n\u003ctd\u003eMPS II (Hunter Syndrome)\u003c\/td\u003e\n\u003ctd\u003eLong-term CAMPSITE Study Data\u003c\/td\u003e\n\u003ctd\u003eReported\u003c\/td\u003e\n\u003ctd\u003eMedian reduction of 85% of cerebrospinal fluid (CSF) levels of heparan sulfate (HS) D2S6.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-202\u003c\/td\u003e\n\u003ctd\u003eDuchenne Muscular Dystrophy (DMD)\u003c\/td\u003e\n\u003ctd\u003ePivotal Trial Enrollment Completion\u003c\/td\u003e\n\u003ctd\u003eOctober 2025\u003c\/td\u003e\n\u003ctd\u003ePhase I\/II data showed microdystrophin expression above the 10% threshold compared to normal in dose level 2 participants.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-202\u003c\/td\u003e\n\u003ctd\u003eDMD\u003c\/td\u003e\n\u003ctd\u003eTopline Results \u0026amp; BLA Submission\u003c\/td\u003e\n\u003ctd\u003eEarly Q2 2026 \u0026amp; Mid-2026\u003c\/td\u003e\n\u003ctd\u003ePotential best-in-class gene therapy.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABBV-RGX-314\u003c\/td\u003e\n\u003ctd\u003eWet AMD\u003c\/td\u003e\n\u003ctd\u003ePivotal Data Readout (Subretinal Delivery)\u003c\/td\u003e\n\u003ctd\u003e2026\u003c\/td\u003e\n\u003ctd\u003eDose level 3 patients demonstrated an 80% reduction in annualized injection rate.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABBV-RGX-314\u003c\/td\u003e\n\u003ctd\u003eDiabetic Retinopathy (DR)\u003c\/td\u003e\n\u003ctd\u003eGlobal Pivotal Program Initiation\u003c\/td\u003e\n\u003ctd\u003eH1 2025\u003c\/td\u003e\n\u003ctd\u003ePhase II data showed 97% reduction in treatment burden at 9 months following treatment in a trial cohort.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003ePipeline progression milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRGX-121 PDUFA target action date of February 8, 2026.\u003c\/li\u003e\n\u003cli\u003eABBV-RGX-314 for DR supported by End-of-Phase II meeting in Q4 2024.\u003c\/li\u003e\n\u003cli\u003eResearch and Development Expenses were $54.4 million for the three months ended September 30, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Advantage is sustained only until the next data readout or approval decision.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 3. Commercial-Ready In-House Manufacturing\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Controls supply chain quality and cost for their own late-stage assets, crucial for launch success.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Few gene therapy companies have a fully operational, FDA-inspected, commercial-scale facility in-house.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Building a GMP facility of this scale is capital-intensive and time-consuming.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Very strong. They initiated commercial supply manufacturing in Q3 2025, showing readiness.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This end-to-end control de-risks the path to market for their key products.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eMetric\/Data Point\u003c\/th\u003e\n\u003cth\u003eAssociated Value\/Amount\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCapacity Scale\u003c\/td\u003e\n\u003ctd\u003eMaximum Vector Production Scale\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e2,000 liters\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability Cost\u003c\/td\u003e\n\u003ctd\u003eInvestment in Manufacturing Innovation Center (as of 12\/31\/2021)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$65 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability Cost\u003c\/td\u003e\n\u003ctd\u003eTotal Investment in Rockville Headquarters (as of 12\/31\/2021)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$100 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Readiness\u003c\/td\u003e\n\u003ctd\u003eCommercial Supply Manufacturing Initiation\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eQ3 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Readiness\u003c\/td\u003e\n\u003ctd\u003eRGX-202 Commercial Batch Capacity\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e2,500 doses\u003c\/strong\u003e per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization Strength\u003c\/td\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities (as of 9\/30\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$302 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe in-house Manufacturing Innovation Center supports end-to-end capabilities:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFacility Size: \u003cstrong\u003e132,000 square feet\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFDA Inspection Status (as of Q3 2025): Completed with \u003cstrong\u003eno observations\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProcess Platform: Implements the proprietary, high-yielding \u003cstrong\u003eNAVXpress™\u003c\/strong\u003e suspension-based manufacturing process.\u003c\/li\u003e\n\u003cli\u003eStaffing: Hired \u003cstrong\u003e200 people\u003c\/strong\u003e over the two years prior to June 2022 in preparation for commercial readiness.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial context for Q3 ended September 30, 2025:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenues: \u003cstrong\u003e$30 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eNet Loss: \u003cstrong\u003e$61.9 million\u003c\/strong\u003e, or $\u003cstrong\u003e1.20\u003c\/strong\u003e basic and diluted net loss per share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 4. High-Value Strategic Partnerships\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nNon-dilutive capital received includes $110.0 million upfront from Nippon Shinyaku in March 2025. The AbbVie collaboration, established in September 2021, included an upfront payment of $370 million with potential for up to $1.38 billion in additional milestones.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePartnership\u003c\/th\u003e\n\u003cth\u003eAsset(s)\u003c\/th\u003e\n\u003cth\u003eUpfront Payment\u003c\/th\u003e\n\u003cth\u003eTotal Potential Milestones\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNippon Shinyaku\u003c\/td\u003e\n\u003ctd\u003eRGX-121, RGX-111\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$700 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAbbVie (Original)\u003c\/td\u003e\n\u003ctd\u003eRGX-314 (sura-vec)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$370 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$1.38 billion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSecuring deals with major players like Nippon Shinyaku and AbbVie is a mark of quality.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThese specific agreements and the trust built are not easily copied.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nSuccessful execution of the AbbVie amendment on August 5, 2025. Secured $110.0 million upfront from Nippon Shinyaku in March 2025. The cash position as of June 30, 2025, was $363.6 million.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAbbVie Amendment (August 2025) includes:\u003c\/li\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$100 million\u003c\/strong\u003e upon first subject dosed in the DR Phase IIb\/III trial.\u003c\/li\u003e\n\u003cli\u003eAdditional \u003cstrong\u003e$100 million\u003c\/strong\u003e upon first subject dosed in a second Phase III clinical trial for DR.\u003c\/li\u003e\n\u003cli\u003eAbbVie will independently advance and pay all costs for a new Phase III ACHIEVE trial in wet AMD.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003e\nThe Nippon Shinyaku deal provided $110.0 million upfront, contributing to a cash balance of $272.7 million as of March 31, 2025, extending the cash runway into the second half of 2026.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 5. Robust Balance Sheet and Cash Runway\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The balance sheet strength supports funding of ongoing operations and clinical trials, specifically for late-stage assets, without immediate reliance on dilutive equity financing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e A strong cash position is inherently valuable, but the current strength is notably bolstered by recent, non-dilutive capital events.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The current financial footing is a direct result of executed strategic transactions, including past financing activities and recent partnership milestones, making the specific timing and quantum difficult to replicate.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The management has successfully positioned the company for sustained operations based on current plans.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e The advantage is temporary, as the cash runway is finite and serves primarily to provide time for value-creating milestones to be achieved.\u003c\/p\u003e\n\u003cp\u003eThe financial position as of the third quarter of 2025 demonstrates this robustness:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\u003c\/th\u003e\n\u003cth\u003eDate\/Period\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$302.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSeptember 30, 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash, Cash Equivalents, and Marketable Securities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$244.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eDecember 31, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUpfront Payment (Nippon Shinyaku Partnership)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$110.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMarch 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Proceeds (Royalty Monetization with HCRx)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$144.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe projection for operational funding is directly linked to this balance:\u003c\/p\u003e\n\u003cp\u003eREGENXBIO projects its balance of \u003cstrong\u003e$302.0 million\u003c\/strong\u003e in cash, cash equivalents, and marketable securities as of September 30, 2025, will fund its operations into \u003cstrong\u003eearly 2027\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eThis guidance is based on current operational plans and excludes potential non-dilutive cash inflows:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMonetization of a Priority Review Voucher (PRV) anticipated upon potential approval of clemidsogene lanparvovec.\u003c\/li\u003e\n\u003cli\u003ePotential development or sales milestone payments from partners or licensees related to MPS programs.\u003c\/li\u003e\n\u003cli\u003ePotential development milestone associated with the diabetic retinopathy program per the AbbVie collaboration.\u003c\/li\u003e\n\u003cli\u003ePotential additional funds from the May 2025 Healthcare Royalty Agreement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 6. Priority Review Voucher (PRV) Optionality\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eA tradable asset with potential monetization in the range of \u003cstrong\u003e$100 million\u003c\/strong\u003e to potentially over \u003cstrong\u003e$150 million\u003c\/strong\u003e based on recent secondary market transactions.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData Point\u003c\/th\u003e\n\u003cth\u003eReference Period\/Context\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage PRV Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSince 2017\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage PRV Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$107 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2020 to November 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRecent High Sale Price\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$150 million\u003c\/strong\u003e or higher\u003c\/td\u003e\n\u003ctd\u003eObserved in multiple recent transactions\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHighest Ever Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$350 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAbbVie purchase in 2015\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExample Recent Sale Price\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$160 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eBavarian Nordic agreement announced June 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eGranted only upon approval of certain rare disease therapies, such as those qualifying under the Rare Pediatric Disease Program. The program issued 11 vouchers in 2024, the most of any year since 2014, with 80 issued in total over the decade.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eZero. It is a regulatory award contingent on meeting specific development criteria, not a replicable internal capability.\u003c\/p\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe potential is directly tied to the RGX-121 BLA, which has a Prescription Drug User Fee Act (PDUFA) goal date of \u003cstrong\u003eFebruary 8, 2026\u003c\/strong\u003e. The pivotal study for RGX-121 involved \u003cstrong\u003e13\u003c\/strong\u003e patients.\u003c\/p\u003e\n\u003cp\u003eRGX-121 has secured several regulatory designations:\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eOrphan Drug Product designation\u003c\/li\u003e\n\u003cli\u003eRare Pediatric Disease designation\u003c\/li\u003e\n\u003cli\u003eFast Track designation\u003c\/li\u003e\n\u003cli\u003eRegenerative Medicine Advanced Therapy (RMAT) status\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary. The value is realized only upon the specific regulatory event (BLA approval) and subsequent voucher monetization or utilization, which is time-bound.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 7. Demonstrated Clinical Efficacy and Differentiation\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Provides the necessary proof points to gain regulatory approval and convince physicians to prescribe.\u003c\/p\u003e\n\u003cp\u003eThe efficacy demonstration for RGX-121 supports a potential first-in-class, one-time treatment for Mucopolysaccharidosis II (MPS II), with the primary endpoint of CSF HS D2S6 reduction at week 16 met. The BLA submission for RGX-121 was completed in 2025, with a potential FDA decision by February 8, 2026.\u003c\/p\u003e\n\u003cp\u003eRGX-202 for Duchenne Muscular Dystrophy demonstrated microdystrophin expression of 77.2% and 46.5% compared to control at three months in two dose level 2 patients.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. Showing 'differentiation against standard of care' is the goal, but achieving it is not guaranteed.\u003c\/p\u003e\n\u003cp\u003eDifferentiation is demonstrated by the potential for patients to discontinue standard of care Enzyme Replacement Therapy (ERT) following RGX-121 treatment.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. Clinical trial results are unique to the specific therapy and patient population.\u003c\/p\u003e\n\u003cp\u003eThe specific long-term biomarker and functional outcomes achieved are unique to the RGX-121 therapy in the CAMPSIITE trial population.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. Positive data for RGX-121, including sustained biomarker reduction, supports the path forward.\u003c\/p\u003e\n\u003cp\u003eThe organization is supported by the progression of the RGX-121 BLA and the financial backing from the Nippon Shinyaku collaboration, which includes an upfront payment of $110 million and up to an additional $700 million in milestones. The company's cash balance as of December 31, 2024, was $244.9 million.\u003c\/p\u003e\n\u003cp\u003eRGX-121 CAMPSIITE Trial Efficacy Data Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eDose Level\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eTimeframe\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian CSF HS D2S6 Reduction\u003c\/td\u003e\n\u003ctd\u003eDL3 (Pivotal)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e85%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained for up to \u003cstrong\u003e2 years\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eERT Discontinuation\/Naïve\u003c\/td\u003e\n\u003ctd\u003eDL3\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e80%\u003c\/strong\u003e of patients\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e18 months\u003c\/strong\u003e post-treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eERT Discontinuation\/Naïve\u003c\/td\u003e\n\u003ctd\u003eDL2\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e71%\u003c\/strong\u003e of patients\u003c\/td\u003e\n\u003ctd\u003eUp to nearly \u003cstrong\u003e3 years\u003c\/strong\u003e post-treatment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedian CSF HS D2S6 Reduction\u003c\/td\u003e\n\u003ctd\u003ePivotal Phase (n=13)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e82%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSustained through \u003cstrong\u003e1 year\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Patients Dosed (Safety)\u003c\/td\u003e\n\u003ctd\u003eAll Phases\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e26\u003c\/strong\u003e patients\u003c\/td\u003e\n\u003ctd\u003eAs of August 20, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. Must be continuously reinforced with new data from other pipeline assets.\u003c\/p\u003e\n\u003cp\u003eThe competitive advantage relies on achieving potential first-in-class status for RGX-121, with anticipated global sales of $460m in 2030. This must be reinforced by the advancement of other assets, such as RGX-202, which is on track for BLA filing in mid-2026, and the AbbVie-partnered ABBV-RGX-314, with pivotal data expected in 2026.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 8. End-to-End AAV Therapy Development Control\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for seamless transition from R\u0026amp;D to clinical trials to commercial supply, reducing handoff risk and timeline delays.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e High. Integrating proprietary vector science, process development, and GMP manufacturing is rare.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High. Requires massive, coordinated investment in facilities and specialized personnel.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. This integration is a core part of their strategy, enabling them to manufacture RGX-202 batches for expected \u003cstrong\u003e2027\u003c\/strong\u003e launch.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. This integrated model is a structural advantage over companies reliant on external CDMOs (Contract Development and Manufacturing Organizations).\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing Innovation Center Investment (Dedicated)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$65 million\u003c\/strong\u003e (Through December 31, 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Headquarters Buildout Investment\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e$100 million\u003c\/strong\u003e (Through December 31, 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFacility Scale (Maximum Capacity)\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e2,000 liters\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-202 Annual Production Capacity\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,500 doses\u003c\/strong\u003e per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-202 Product Purity (Full Capsids)\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e80%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-121 Manufacturing Inspection Status\u003c\/td\u003e\n\u003ctd\u003ePre-license inspection (PLI) with \u003cstrong\u003eno observations\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePersonnel Hired (for end-to-end capabilities)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e200 people\u003c\/strong\u003e (Over two years leading up to June 2022)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe end-to-end control supports key product timelines:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRGX-202: Top-line pivotal data expected in early Q2 \u003cstrong\u003e2026\u003c\/strong\u003e; BLA submission mid-\u003cstrong\u003e2026\u003c\/strong\u003e; commercial launch preparations for \u003cstrong\u003e2027\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eRGX-121: Anticipated FDA approval by early next year (relative to late 2025 reporting).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe company has manufactured the first batches of RGX-202 intended for commercial supply.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eREGENXBIO Inc. (RGNX) - VRIO Analysis: 9. Focused Portfolio on High-Unmet-Need Markets\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Targets diseases where payers are more willing to adopt high-cost, one-time curative therapies. The strategic focus is on late-stage assets: ABBV-RGX-314 (retinal), RGX-202 (Duchenne), and RGX-121 (MPS II).\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate. The pipeline targets rare diseases like Mucopolysaccharidosis Type II (MPS II) and Duchenne Muscular Dystrophy (DMD), alongside large retinal markets like wet AMD and Diabetic Retinopathy (DR). RGX-121 is positioned as a potential first-in-class one-time treatment for MPS II.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low. The focus is supported by proprietary technology; RGX-202 for Duchenne is noted as the only investigational microdystrophin gene therapy construct including the C-Terminal (CT) domain.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Strong. A strategic restructuring in late 2023 involved a 15% workforce reduction, projected to yield total savings of at least $100 million to extend cash runway. The company reported cash, cash equivalents and marketable securities of $302.0 million as of September 30, 2025, expected to fund operations into early 2027.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained. The focused approach allows for concentrated capital allocation toward these differentiated programs.\u003c\/p\u003e\n\n\u003cp\u003eThe focused portfolio is detailed below, highlighting key financial triggers:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\u003c\/td\u003e\n\u003ctd\u003eIndication Focus\u003c\/td\u003e\n\u003ctd\u003eKey Financial Trigger\/Partner\u003c\/td\u003e\n\u003ctd\u003ePotential Near-Term Payment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-121\u003c\/td\u003e\n\u003ctd\u003eMPS II (Hunter Syndrome)\u003c\/td\u003e\n\u003ctd\u003eNippon Shinyaku Partnership\u003c\/td\u003e\n\u003ctd\u003eUpfront of \u003cstrong\u003e$110.0 million\u003c\/strong\u003e received in Q1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRGX-202\u003c\/td\u003e\n\u003ctd\u003eDuchenne Muscular Dystrophy\u003c\/td\u003e\n\u003ctd\u003eBLA Submission Mid-2026 Target\u003c\/td\u003e\n\u003ctd\u003eNo immediate public milestone payment specified for this period\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eABBV-RGX-314\u003c\/td\u003e\n\u003ctd\u003eWet AMD \/ Diabetic Retinopathy (DR)\u003c\/td\u003e\n\u003ctd\u003eAbbVie Collaboration Amendment (Aug 2025)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$100 million\u003c\/strong\u003e upon first subject dosed in Phase IIb\/III trial (DR)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eKey late-stage pipeline assets include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRGX-121 (MPS II): BLA submission expected completion Q1 2025. Potential Priority Review Voucher (PRV) receipt in 2025.\u003c\/li\u003e\n\u003cli\u003eRGX-202 (Duchenne): Pivotal trial enrollment completion expected in 2025.\u003c\/li\u003e\n\u003cli\u003eABBV-RGX-314 (Retinal): AbbVie to independently advance and pay all costs for a new Phase III ACHIEVE trial in wet AMD.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eFinance: 13-Week Cash Flow View Incorporating Expected Milestone Payments by Friday\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAssuming the current reporting period begins immediately following the September 30, 2025 balance, the view would incorporate expected operational burn and potential near-term milestone receipts based on trial progress, such as the $100 million DR milestone from AbbVie upon first subject dosed in the Phase IIb\/III trial.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Flow Item\u003c\/td\u003e\n\u003ctd\u003eWeek 1-4 (Hypothetical)\u003c\/td\u003e\n\u003ctd\u003eWeek 5-8 (Hypothetical)\u003c\/td\u003e\n\u003ctd\u003eWeek 9-13 (Hypothetical)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBeginning Cash Balance (Est. from $302.0M as of 9\/30\/25)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$302.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e$295.5 million\u003c\/td\u003e\n\u003ctd\u003e$288.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Used in Operations (Est. Weekly Burn)\u003c\/td\u003e\n\u003ctd\u003e($6.5 million)\u003c\/td\u003e\n\u003ctd\u003e($7.5 million)\u003c\/td\u003e\n\u003ctd\u003e($10.0 million)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eExpected Milestone Payment (e.g., AbbVie DR Dosing)\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e$0\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnding Cash Balance (Projected)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$295.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$288.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$388.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516241272981,"sku":"rgnx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/rgnx-vrio-analysis.png?v=1740210266","url":"https:\/\/dcf-model.com\/fr\/products\/rgnx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}